[go: up one dir, main page]

BRPI0404050A - Uso de um composto ou de um seu sal ou éster farmaceuticamente aceitável, formulação farmacêutica, formulação acondicionada, composto, e, método para prevenir e/ou tratar hiperplasia benigna da próstata em pacientes em necessidade de tal prevenção ou tratamento - Google Patents

Uso de um composto ou de um seu sal ou éster farmaceuticamente aceitável, formulação farmacêutica, formulação acondicionada, composto, e, método para prevenir e/ou tratar hiperplasia benigna da próstata em pacientes em necessidade de tal prevenção ou tratamento

Info

Publication number
BRPI0404050A
BRPI0404050A BR0404050-3A BRPI0404050A BRPI0404050A BR PI0404050 A BRPI0404050 A BR PI0404050A BR PI0404050 A BRPI0404050 A BR PI0404050A BR PI0404050 A BRPI0404050 A BR PI0404050A
Authority
BR
Brazil
Prior art keywords
compound
prevention
pharmaceutically acceptable
ester
formulation
Prior art date
Application number
BR0404050-3A
Other languages
English (en)
Inventor
Luciano Adorini
Enrico Colli
Original Assignee
Bioxell Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0322395A external-priority patent/GB0322395D0/en
Priority claimed from GB0325598A external-priority patent/GB2407499B/en
Priority claimed from GB0416876A external-priority patent/GB0416876D0/en
Application filed by Bioxell Spa filed Critical Bioxell Spa
Publication of BRPI0404050A publication Critical patent/BRPI0404050A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/04—Drugs for disorders of the urinary system for urolithiasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

"USO DE UM COMPOSTO OU DE UM SEU SAL OU éSTER FARMACEUTICAMENTE ACEITáVEL, FORMULAçãO FARMACêUTICA, FORMULAçãO ACONDICIONADA, COMPOSTO, E, MéTODO PARA PREVENIR E/OU TRATAR HIPERPLASIA BENIGNA DA PRóSTATA EM PACIENTES EM NECESSIDADE DE TAL PREVENçãO OU TRATAMENTO". O invento refere-se à utilização de 1-alfa-fluoro-25hidróxi-16,23E-dieno-26,27-bis-homo-20-epi-colecalc iferol, ou de um seu sal ou éster farmaceuticamente aceitável, para o fabrico de um medicamento para a prevenção e/ou tratamento de hiperplasia benigna da próstata (HBP) e sintomas associados.
BR0404050-3A 2003-09-24 2004-09-22 Uso de um composto ou de um seu sal ou éster farmaceuticamente aceitável, formulação farmacêutica, formulação acondicionada, composto, e, método para prevenir e/ou tratar hiperplasia benigna da próstata em pacientes em necessidade de tal prevenção ou tratamento BRPI0404050A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0322395A GB0322395D0 (en) 2003-09-24 2003-09-24 Methods for treating bladder dysfunction and related compounds and compositions
GB0325598A GB2407499B (en) 2003-11-03 2003-11-03 Vitamin D3 analogue for use in the treatment of BPH
GB0416876A GB0416876D0 (en) 2004-07-29 2004-07-29 Compound and use in treatment

Publications (1)

Publication Number Publication Date
BRPI0404050A true BRPI0404050A (pt) 2005-06-14

Family

ID=34229055

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0404050-3A BRPI0404050A (pt) 2003-09-24 2004-09-22 Uso de um composto ou de um seu sal ou éster farmaceuticamente aceitável, formulação farmacêutica, formulação acondicionada, composto, e, método para prevenir e/ou tratar hiperplasia benigna da próstata em pacientes em necessidade de tal prevenção ou tratamento

Country Status (11)

Country Link
EP (1) EP1673096A1 (pt)
JP (2) JP2007506699A (pt)
CN (1) CN100488511C (pt)
BE (1) BE1016292A3 (pt)
BR (1) BRPI0404050A (pt)
CH (1) CH698144B1 (pt)
EA (1) EA010240B1 (pt)
FR (1) FR2859910B1 (pt)
NL (1) NL1027109C2 (pt)
NZ (1) NZ535531A (pt)
WO (1) WO2005027923A1 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1800677A4 (en) * 2004-10-05 2008-04-02 Kissei Pharmaceutical AGENT FOR THE PROPHYLACTIC OR THERAPEUTIC TREATMENT OF URINE COLLECTION DISORDERS IN BLADDER OF THE BLADDER OF THE LOWER URINARY CANAL
EP1806136B1 (en) * 2004-10-06 2011-11-30 Kissei Pharmaceutical Co., Ltd. Medicinal composition for prevention of transition to operative treatment for prostatic hypertrophy
US20100009949A1 (en) * 2006-03-24 2010-01-14 Bioxell S.P.A. Novel method
US8221803B1 (en) 2007-06-25 2012-07-17 OncoNatural Solutions, Inc. Composition for prostate health
US20120164240A1 (en) 2010-12-22 2012-06-28 Audino David Lawrence Enriched a. blitoides compositions and uses thereof
US20170049834A1 (en) * 2015-08-18 2017-02-23 Golden Biotechnology Corporation Benign prostatic hyperplasia add-on therapy
FR3063906B1 (fr) * 2017-03-20 2025-12-12 Pf Medicament Utilisation de l'oleoresine de copaifera dans les pathologies de la prostate

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5763429A (en) * 1993-09-10 1998-06-09 Bone Care International, Inc. Method of treating prostatic diseases using active vitamin D analogues
TW403735B (en) * 1995-11-22 2000-09-01 Hoffmann La Roche 25-hydroxy-16-ene-26, 27-bishomo-cholecalciferol
SG70009A1 (en) * 1996-05-23 2000-01-25 Hoffmann La Roche Vitamin d3 analogs
EP0981523B1 (en) * 1997-05-16 2005-12-07 Woman & Infants Hospital Cyclic ether vitamin d3 compounds, 1alpha (oh) 3-epi-vitamin d3 compounds and uses thereof
US5872113A (en) * 1997-05-16 1999-02-16 Syntex (U.S.A.) Inc. Fluorinated vitamin D3 analogs
US6255501B1 (en) * 1999-04-26 2001-07-03 Hoffman-La Roche Inc. Process for preparing antiosteoporotic agents
WO2003034961A1 (en) * 2001-10-23 2003-05-01 Euro-Celtique, S.A. Terazosin transdermal device and methods
JP2005515996A (ja) * 2001-12-03 2005-06-02 ノバセア インコーポレイティッド 活性型ビタミンｄ化合物を含む薬学的組成物

Also Published As

Publication number Publication date
EA200401100A1 (ru) 2005-04-28
HK1085373A1 (zh) 2006-08-25
FR2859910A1 (fr) 2005-03-25
EP1673096A1 (en) 2006-06-28
NZ535531A (en) 2006-03-31
CN100488511C (zh) 2009-05-20
FR2859910B1 (fr) 2006-04-28
JP2007506699A (ja) 2007-03-22
NL1027109C2 (nl) 2005-05-03
JP2009035559A (ja) 2009-02-19
BE1016292A3 (nl) 2006-07-04
WO2005027923A1 (en) 2005-03-31
CH698144B1 (fr) 2009-05-29
NL1027109A1 (nl) 2005-03-29
EA010240B1 (ru) 2008-06-30
CN1615891A (zh) 2005-05-18

Similar Documents

Publication Publication Date Title
BRPI0406667A (pt) Método para o tratamento de câncer, e, formulação terapeuticamente aceitável de 2-dg
ATE307608T1 (de) Kombination von doctaxel und rhumab her2 zür krebsbehandlung
BR0209365A (pt) Usos farmacêuticos de bisfosfonatos
BR0115109A (pt) Agentes terapêuticos e métodos de uso dos mesmos para a modulação da angiogênese
BR0110877A (pt) Métodos de tratamento de câncer primário, de aumento da dosagem de um inibidor de topoisomerase, de redução ou prevenção de um efeito adverso associado com quimioterapia e com terapia de radiação, de aumento da eficácia terapêutica de um inibidor de topoisomerase, e de proteção de um paciente canceroso dos efeitos adversos associados com a administração de uma droga anti-câncer, composição farmacêutica, forma de dosagem, e, kit para uso no tratamento de câncer
BRPI0415007A (pt) método para tratar, prevenir, modificar ou administrar dor, e, composição farmacêutica
BR0109446A (pt) Medicamento para a aplicação intracorpórea, uso de um xanteno halogenado, composição farmacêutica, e, método de tratamento
DE60115029D1 (de) Pharmazeutische zusammensetzungen enthaltend cannabidiol-derivate
MXPA03010085A (es) Composiciones y su uso en la hiperplasia.
BR0113447A (pt) Método de tratamento ou prevenção do câncer em um ser humano, e, composição farmacêutica
DE60026538D1 (de) Pharmazeutische zubereitungen die clavulansäure oder derivate enthalten zur behandlund von neurologischen störungen
WO1994008551A3 (en) Pharmaceutical compositions and methods for treating cold symptoms
WO2001068125A3 (en) Methods and compositions for the treatment and prevention of erectile dysfunction
WO2004039325A3 (en) Treatment of pain with jnk inhibitors
BRPI0406796A (pt) Métodos para tratar hipertrofia prostática benigna, para reduzir um sintoma associado com a mesma, para reduzir o tamanho da próstata em um indivìduo humano e para profilaxia de bhp, composição farmacêutica oral de dose unitária, e, uso de lonidamina ou um análogo de lonidamina
BR0315593A (pt) Método de tratar, prevenir, modificar ou controlar dor e composição farmacêutica
WO2007062093A3 (en) Combination therapy for the treatment of cancer comprising a metalloprotease inhibitor
MY118986A (en) Use of (alpha)-1-adrenoreceptor antagonists in the prevention and treatment of benign prostatic hyperplasia
BRPI0404050A (pt) Uso de um composto ou de um seu sal ou éster farmaceuticamente aceitável, formulação farmacêutica, formulação acondicionada, composto, e, método para prevenir e/ou tratar hiperplasia benigna da próstata em pacientes em necessidade de tal prevenção ou tratamento
AU7862401A (en) Pharmaceutical compostion comprising trkaig2 for use in the prevention and/or treatment of cancer
TW200420290A (en) Methods for the treatment, prevention and management of macular degeneration
Schulmeister Totect™: A new agent for treating anthracycline extravasation
BR0315609A (pt) Método de tratar, prevenir, modificar ou controlar dor e composição farmacêutica
TR200103418T2 (tr) Melatoninin tedavi edici kullanımı.
PL368686A1 (en) Novel aminobenzoephenones

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according art. 34 industrial property law
B08F Application fees: dismissal - article 86 of industrial property law

Free format text: REFERENTE A 7A ANUIDADE.

B08K Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87)

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2159 DE 22/05/2012.